Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

Vijaya Raj Bhatt, Christopher Wichman, Zaid S. Al-Kadhimi, Thuy T. Koll, Alfred L Fisher, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori Maness, Krishna Gundabolu

Blood (2022) 140 (Supplement 1): 8991–8992.

https://doi.org/10.1182/blood-2022-156310

Published: 2022

Journal Articles

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Vijaya Raj Bhatt, Christopher Wichman, Alyssa C. Bouska, Lori Maness, Zaid S. Al-Kadhimi, Javeed Iqbal, James E. Talmadge, Krishna Gundabolu

Blood (2022) 140 (Supplement 1): 12918–12919.

https://doi.org/10.1182/blood-2022-156316

Published: 2022

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

Krishna Gundabolu, Vijaya R. Bhatt, Lynette M. Smith, Valerie K Shostrom, Lori J. Maness, Zaid S. Al-Kadhimi, Julie M. Vose, R. Gregory Bociek, Matthew A. Lunning, Avyakta Kallam, Christopher D'Angelo, Muhamed Baljevic, Apar K Ganti

Blood (2021) 138 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2021-148945

Published: 2021

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)

Vijaya R. Bhatt, MD, Valerie K Shostrom, Sarah A. Holstein, MD PhD, Zaid S. Al-Kadhimi, MD, Lori J. Maness, MD, Ann Berger, PhD APRN-CNS, AOCNS, FAAN, James O. Armitage, MD, Krishna Gundabolu, MBBS

Blood (2019) 134 (Supplement_1): 2155.

https://doi.org/10.1182/blood-2019-122679

Published: 2019

Journal Articles

The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience

Madeline Skousen, Sarah A. Holstein, MD PhD, Matthew A. Lunning, DO, FACP, Elizabeth R. Lyden, MS, Gilmore Sheree, BA, Kimberly Schmit-Pokorny, Nurse Manager, James O. Armitage, MD, Zaid S. Al-Kadhimi, MD, Julie M Vose, MDMBA, Muhamed Baljevic, MD

Blood (2019) 134 (Supplement_1): 2028.

https://doi.org/10.1182/blood-2019-131594

Published: 2019

Journal Articles

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML)

Vijaya R. Bhatt, MD, Christopher Wichman, PhD, Zaid S. Al-Kadhimi, MD, Thuy T. Koll, MD, Ann Berger, PhD APRN-CNS, AOCNS, FAAN, James O. Armitage, MD, Sarah A. Holstein, MD PhD, Krishna Gundabolu, MBBS, Lori J. Maness, MD

Blood (2019) 134 (Supplement_1): 120.

https://doi.org/10.1182/blood-2019-124375

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Prevalence and Effects of Polypharmacy on Overall Survival (OS) of Acute Myeloid Leukemia (AML)

Prajwal Dhakal, MBBS, Elizabeth R. Lyden, MS, Kate-Lynn E Muir, MD, Zaid S. Al-Kadhimi, MD, Thuy T. Koll, MD, Lori J. Maness, MD, Krishna Gundabolu, MBBS, Vijaya R. Bhatt, MD

Blood (2019) 134 (Supplement_1): 5086.

https://doi.org/10.1182/blood-2019-124000

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation for Multiple Myeloma: A 34-Year Experience

Courtney Venegas, BA, Matthew A. Lunning, DO, Zaid S. Al-Kadhimi, MD, Vijaya R. Bhatt, MD, Elizabeth R. Lyden, MS, Kimberly Schmit-Pokorny, Nurse Manager, James O. Armitage, MD, Julie M. Vose, MD MBA, Sarah A. Holstein, MD PhD, Muhamed Baljevic, MD

Blood (2018) 132 (Supplement 1): 5780.

https://doi.org/10.1182/blood-2018-99-116990

Published: 2018

Journal Articles

Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) – A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT).

Mayur S Ramesh, MD, Archana Thakur, PhD, Philip Pellett, PhD, Subhendu Das, PhD, Zaid S Al-Kadhimi, MD, Lawrence G Lum, MD, DSc

Blood (2009) 114 (22): 1157.

https://doi.org/10.1182/blood.V114.22.1157.1157

Published: 2009

Journal Articles

The Combination of Tacrolimus (T), Sirolimus (S), and Rabbit Anti-Thymocyte Globulin (Thymoglobulin Thymo) to Prevent Acute Graft-Vs-Host Disease (aGVHD) in Patients (pts) Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT).

Zaid S Al-Kadhimi, M.D, Zartash Gul, MD, Lawrence G. Lum, MD, DSC, Lois Ayash, MD, Muneer H. Abidi, MD, Wei Chen, PhD, Alice Mitchell, BS, Voravit Ratanatharathorn, M.D, Joseph Uberti, M.D., Ph.D

Blood (2009) 114 (22): 2239.

https://doi.org/10.1182/blood.V114.22.2239.2239

Published: 2009

Journal Articles

The Use of Clinical Grade Magnetic Beads to Deplete Immune Suppressive Elements from Autologous Peripheral Blood Hematopoietic Stem Cell Grafts Enhances T Cell Immune Responses.

Zaid S Al-Kadhimi, M.D., Haider Mahdi, M.D, Moshrik Abdalamir, M.D, Elyse Paul, Voravit Ratanatharathorn, M.D, Joseph Uberti, M.D, Ph.D, Lawrence G. Lum, MD, DSC

Blood (2008) 112 (11): 2311.

https://doi.org/10.1182/blood.V112.11.2311.2311

Published: 2008

Journal Articles

Early Goal Directed Therapy for Septic Shock Is Feasible and Safe in Hematopoietic Stem Cell Transplant Patients.

Zaid S. Al-Kadhimi, MD, Argelia J. Sandoval, M.D., Jasmine M. Zain, M.D., Stephen J. Forman, M.D.

Blood (2006) 108 (11): 5295.

https://doi.org/10.1182/blood.V108.11.5295.5295

Published: 2006

NARROW

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)

The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML)

Prevalence and Effects of Polypharmacy on Overall Survival (OS) of Acute Myeloid Leukemia (AML)

Allogeneic Stem Cell Transplantation for Multiple Myeloma: A 34-Year Experience

Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) – A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT).

The Combination of Tacrolimus (T), Sirolimus (S), and Rabbit Anti-Thymocyte Globulin (Thymoglobulin Thymo) to Prevent Acute Graft-Vs-Host Disease (aGVHD) in Patients (pts) Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT).

The Use of Clinical Grade Magnetic Beads to Deplete Immune Suppressive Elements from Autologous Peripheral Blood Hematopoietic Stem Cell Grafts Enhances T Cell Immune Responses.

Early Goal Directed Therapy for Septic Shock Is Feasible and Safe in Hematopoietic Stem Cell Transplant Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only